Epigenetic reprogramming in cancer: From diagnosis to treatment
Frontiers in Cell and Developmental Biology · 14.02.2023 · 11
DOI: 10.3389/fcell.2023.1116805 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 14.02.2023. Verfasst von Pedro Mikael da Silva Costa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceará, Fortaleza, Ceará, Brazil. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 225 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Disruption of the epigenetic program of gene expression is a hallmark of cancer that initiates and propagates tumorigenesis. Altered DNA methylation, histone modifications and ncRNAs expression are a feature of cancer cells. The dynamic epigenetic changes during oncogenic transformation are related to tumor heterogeneity, unlimited self-renewal and multi-lineage differentiation. This stem cell-like state or the aberrant reprogramming of cancer stem cells is the major challenge in treatment and drug resistance. Given the reversible nature of epigenetic modifications, the ability to restore the cancer epigenome through the inhibition of the epigenetic modifiers is a promising therapy for cancer treatment, either as a monotherapy or in combination with other anticancer therapies, including immunotherapies. Herein, we highlighted the main epigenetic alterations, their potential as a biomarker for early diagnosis and the epigenetic therapies approved for cancer treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceará, Fortaleza, Ceará, Brazil.
- Postgraduation Program in Biotechnology Northeastern Network of Biotechnology, Federal University of Ceará, Fortaleza, Ceará, Brazil.
- Postgraduation Program in Pharmacology, Federal University of Ceará, Fortaleza, Ceará, Brazil.
- Oswaldo Cruz Foundation, FIOCRUZ-Ceará, Sector of Biotechnology, Eusebio, Ceará, Brazil.
- Postgraduation Program in Biotechnology and Natural Resources, Federal University of Ceará, Fortaleza, Ceará, Brazil.
- Drug Research and Development Center, Postgraduate Program in Translational Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Zitieren
APA
Costa, P. M. D. S., Sales, S. L. A., Pinheiro, D. P., Pontes, L. Q., Maranhão, S. S., Pessoa, C. D. Ó., Furtado, G. P., & Furtado, C. L. M. (2023). Epigenetic reprogramming in cancer: From diagnosis to treatment. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1116805
Vancouver
Costa PMDS, Sales SLA, Pinheiro DP, Pontes LQ, Maranhão SS, Pessoa CDÓ, et al. Epigenetic reprogramming in cancer: From diagnosis to treatment. Frontiers in Cell and Developmental Biology. 2023;11. doi:10.3389/fcell.2023.1116805
BibTeX
@article{Costa2023,
author = {Costa, Pedro Mikael da Silva and Sales, Sarah Leyenne Alves and Pinheiro, Daniel Pascoalino and Pontes, Larissa Queiroz and Maranhão, Sarah Sant'Anna and Pessoa, Claudia do Ó and Furtado, Gilvan Pessoa and Furtado, Cristiana Libardi Miranda},
title = {Epigenetic reprogramming in cancer: From diagnosis to treatment},
journal = {Frontiers in Cell and Developmental Biology},
year = {2023},
volume = {11},
doi = {10.3389/fcell.2023.1116805}
}
EUVIMED